Testosterone Optimization
A phased framework addressing the HPG axis, GH/IGF-1 axis, anti-inflammatory foundation, cellular energy environment, and sexual function pathways simultaneously — prioritizing endogenous production over exogenous replacement.
Testosterone decline is not a single failure. It’s a cascade — a sequential breakdown of one of the most complex hormonal signaling systems in the male body. Understanding it matters because the intervention that actually works has to address where in the cascade things are going wrong, not just the end result.
The system responsible for testosterone production is called the HPG axis — Hypothalamic-Pituitary-Gonadal. It operates as a chain of signals:
When the chain works correctly, GnRH is released in pulses every 90–120 minutes. Those pulses drive LH release from the pituitary. LH tells the Leydig cells in the testes to produce testosterone. The system self-regulates via negative feedback — rising testosterone tells the hypothalamus to ease off GnRH.
In most cases of declining testosterone, the failure isn’t at the testes. The testes are often capable of producing testosterone — they’re just not receiving adequate signaling. The problem is upstream.
Exogenous testosterone (injections, gels, pellets) immediately suppresses LH via negative feedback. With no LH signal reaching the testes, intratesticular testosterone — which is critical for sperm production and which exists at concentrations 50–100x higher than serum T — collapses. The testes atrophy. Fertility is compromised. The subject becomes dependent on exogenous supply. This protocol takes the opposite approach: restore the cascade, don’t replace it.
The four main suppressors — the actual root causes of HPG axis dysfunction in most aging men:
🔥 Chronic Inflammation
Elevated TNF-α and IL-6 directly suppress GnRH neurons in the hypothalamus via NF-κB signaling. Systemic inflammation — from diet, poor gut health, or chronic stress — acts as a persistent brake on the entire cascade. Addressing inflammation before stimulating the axis is not optional; it’s the prerequisite.
😴 Sleep Disruption
Approximately 70% of daily testosterone secretion occurs during sleep, driven by nocturnal LH pulses that peak during slow-wave sleep. A single week of sleep restricted to 5 hours reduces serum testosterone 10–15% acutely. Chronic poor sleep architecture creates chronic low-grade testosterone suppression that no amount of stimulation can fully overcome.
🏋️ Metabolic Dysfunction
Insulin resistance and central adiposity are among the strongest predictors of low testosterone in aging men. Visceral fat is metabolically active — it’s packed with aromatase enzyme, which converts testosterone to estradiol. Higher estradiol then suppresses LH via feedback. Improving insulin sensitivity and reducing visceral fat breaks this cycle.
📉 GH Axis Decline
Growth hormone declines 14–15% per decade after age 30. IGF-1 — GH’s primary downstream mediator — directly stimulates Leydig cell steroidogenesis. Men with low GH have impaired testicular T production even with adequate LH signaling. The HPG and GH axes are not independent; they work in parallel.
None of these suppressors operate in isolation. Chronic inflammation worsens insulin resistance. Poor sleep elevates cortisol which worsens inflammation. Metabolic dysfunction worsens sleep quality. GH decline accelerates body composition changes that increase aromatase activity. By the time serum testosterone is measurably low, a man is usually dealing with all four suppressors simultaneously — which is why single-intervention approaches rarely produce lasting results.
This protocol is built around one central principle: restore the system rather than replace it. Every compound selected either removes a suppressor, restores a signaling step in the cascade, or supports the physiological conditions under which the cascade can function correctly.
Phase 1 addresses the suppressors first — inflammation (KLOW) and intratesticular production (HCG). There’s no point in stimulating GnRH pulsatility if NF-κB is actively suppressing the neurons you’re trying to activate. Phase 2 introduces Kisspeptin-10 to restore the natural upstream cascade, and the GH 2X blend to address the parallel IGF-1 pathway. Phase 3 adds the metabolic and sleep-architecture components that sustain the gains long-term. This is a build, not a blast.
HCG anchors the protocol throughout all three phases because it provides a floor — direct Leydig cell stimulation that maintains production regardless of what’s happening upstream. Kisspeptin then rebuilds the signaling architecture so the body’s own pulsatile LH can do increasing amounts of the work as the protocol progresses. The goal by Week 12 is a system that is better positioned to sustain itself — not one that has simply been flooded with a synthetic signal and will crash when that signal is removed.
The GH axis intervention runs in parallel because IGF-1’s direct effect on Leydig steroidogenesis is not a minor contribution. In men over 40, restoring GH pulsatility is frequently as impactful on total testosterone as the HPG axis interventions themselves.
HCG is structurally identical to LH at the receptor level. It binds the LH/hCG receptor on Leydig cells and triggers the same cAMP-PKA signaling cascade that LH would — stimulating testosterone synthesis directly inside the testes. This is the only compound in the protocol that directly produces testosterone rather than signaling the body to produce it.
The critical distinction from exogenous testosterone: HCG stimulates intratesticular testosterone (ITT), which exists at concentrations 50–100x higher than serum T and is essential for spermatogenesis. Exogenous testosterone suppresses LH, collapses ITT, and causes testicular atrophy. HCG maintains the machinery.
Serum total testosterone rises within 2–3 weeks. Morning erections often return by Week 3–4 as the first noticeable subjective marker. Testicular volume maintained or slightly increased vs. pre-protocol baseline. Monitor E2 — rising T will increase aromatization, especially in the first month.
Coviello et al., 2005. “Effects of graded doses of testosterone on erythropoiesis in healthy young and older men.” JCEM. | Ramasamy et al., 2014. “Testosterone supplementation versus clomiphene citrate for hypogonadism.” BJU International.
Kisspeptin neurons in the hypothalamus represent the most upstream activator of the entire HPG axis. KISS1 neurons project directly onto GnRH neurons and are required for pulsatile GnRH release. Without kisspeptin signaling, the GnRH pulse generator goes quiet — LH drops, FSH drops, and testosterone follows.
Kisspeptin-10 is the biologically active C-terminal decapeptide fragment of the full kisspeptin-54 molecule. A single 1 mcg/kg subcutaneous dose produces a robust LH surge within 30–60 minutes — not a small, incremental signal, but a 10–18x elevation over baseline. This drives downstream FSH and testosterone production through the intact cascade.
Why pulsatile administration is non-negotiable: GnRH receptors desensitize rapidly under continuous stimulation — this is the same mechanism used in GnRH agonist therapies to suppress testosterone in prostate cancer. Continuous kisspeptin infusion produces the same desensitization. Every 12 hours or EOD dosing preserves receptor sensitivity and maintains the pulsatile character of the natural signal. This is not a nuance; it’s the difference between the compound working and it doing the opposite of what’s intended.
LH should remain measurable on bloodwork (unlike with exogenous TRT where it suppresses to near-zero). FSH often rises modestly. Total T continues to climb on top of HCG baseline. Libido and psychological wellbeing often improve more noticeably with Kisspeptin than with HCG alone — likely reflecting the full downstream cascade vs. direct receptor bypass.
Dhillo et al., 2007. “Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.” JCEM. | Jayasena et al., 2011. “Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.” JCEM.
These two compounds work synergistically through different but complementary mechanisms. CJC-1295 No DAC is a GHRH analog — it stimulates the pituitary to release GH by binding GHRH receptors. Ipamorelin is a selective ghrelin mimetic — it amplifies the GH pulse amplitude and simultaneously suppresses somatostatin (the natural brake on GH release). Together, they produce a clean, high-amplitude, pulsatile GH release that closely mimics the body’s own nocturnal GH pulses.
The testosterone connection is direct: IGF-1, produced primarily in the liver in response to GH, directly stimulates Leydig cell steroidogenesis. Leydig cells express IGF-1 receptors, and IGF-1 potentiates LH-stimulated testosterone production via multiple intracellular pathways. In men with declining GH, this parallel steroidogenic input is progressively lost — restoring it produces meaningful additive effects on testosterone output even when HPG signaling is being optimized simultaneously.
Ipamorelin’s selectivity matters: unlike GHRP-2 or GHRP-6, it does not stimulate cortisol or prolactin release at standard doses. Elevated cortisol directly suppresses HPG axis function and Leydig cell steroidogenesis — using a non-selective secretagogue would partially undermine the protocol’s primary objective.
Mild fluid retention in Weeks 1–4 as IGF-1 rises — this is normal and resolves. Improved sleep quality often noted by Week 2 (GH pulses during slow-wave sleep improve sleep architecture). Body composition changes — reduced visceral fat, improved lean mass — typically become noticeable by Week 6–8. IGF-1 bloodwork at Week 6 will confirm axis response.
Rudman et al., 1990. “Effects of human growth hormone in men over 60 years old.” NEJM. | Juul et al., 2002. “Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease.” JCEM.
KLOW is a multi-peptide blend formulated to address the inflammatory component of HPG suppression from several angles simultaneously. Its four components each target a distinct aspect of the inflammatory and tissue environment:
BPC-157 (Body Protection Compound) — a 15-amino-acid peptide derived from human gastric juice. Stimulates angiogenesis via VEGF, accelerates connective tissue repair, exhibits systemic anti-inflammatory effects, and has demonstrated protective effects on GI mucosal integrity. Emerging evidence suggests direct modulation of the dopaminergic and serotonergic systems, with potential effects on GnRH neuron function.
TB-500 (Thymosin Beta-4) — the primary actin-sequestering peptide in mammalian cells. Promotes cellular migration, angiogenesis, and tissue remodeling. Reduces inflammatory cytokine expression (particularly IL-1β and TNF-α). The systemic reduction in pro-inflammatory signaling is the primary mechanism relevant to HPG restoration.
KPV (Lys-Pro-Val) — a tripeptide fragment of α-MSH with potent NF-κB inhibitory activity. NF-κB is the master transcription factor for inflammatory gene expression and is the primary mechanism by which systemic inflammation suppresses hypothalamic GnRH neurons. KPV’s direct NF-κB inhibition acts as a targeted interruption of this suppression pathway.
GHK-Cu (Copper peptide) — a naturally occurring plasma tripeptide that declines significantly with age. Activates antioxidant defense systems, promotes collagen synthesis, has demonstrated neuroprotective effects, and upregulates VEGF. Its inclusion addresses the oxidative stress component of hypothalamic inflammation.
KLOW is not a compound you cycle indefinitely — it’s a platform cleaner. Four weeks is sufficient to reduce the inflammatory burden that’s been suppressing the cascade. By Week 5, when Kisspeptin is introduced, the hypothalamic environment has been prepared. Continuing beyond Week 4 provides diminishing returns for HPG restoration specifically.
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed from research into the pineal gland by the St. Petersburg Institute of Bioregulation and Gerontology. Its primary mechanism in this protocol is restoration of pineal melatonin synthesis — but the downstream effects extend well beyond sleep.
The pineal connection to testosterone is underappreciated. Melatonin regulates the circadian expression of GnRH neurons — the overnight LH pulses that drive the majority of daily testosterone production are dependent on intact melatonin signaling. In aging men, pineal calcification and melatonin decline directly impair the nocturnal LH pulsatility that accounts for approximately 70% of testosterone secretion. Restoring melatonin rhythm via Epitalon restores the hormonal environment in which LH can pulse optimally during slow-wave sleep.
The secondary mechanism is telomerase activation. Epitalon has demonstrated the ability to activate telomerase and elongate telomeres in somatic cells in multiple studies — a finding with broader cellular longevity implications beyond the scope of this protocol’s primary objective, but worth noting for subjects interested in comprehensive longevity strategies.
The 10-day course format prevents receptor desensitization while delivering sufficient stimulation to normalize the melatonin circadian rhythm. Effects typically persist 3–6 months after a single course, making it appropriate to run once at Week 6 (when the protocol’s foundation is established) rather than continuously.
Sleep quality improvement is often the first reported effect — specifically deeper sleep and more vivid dreams, consistent with restored slow-wave architecture. Morning testosterone measurements (which should already be rising from HCG and Kisspeptin) often show an additional upward shift in the weeks following Epitalon use as nocturnal LH pulsatility improves.
Khavinson & Morozov, 2003. “Peptides of pineal gland and thymus prolong human life.” Neuroendocrinology Letters. | Anisimov et al., 2006. “Melatonin increases both life span and tumor incidence in female CBA mice.” JGBS.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a mitochondrial-derived peptide — one of the first identified members of a class of signaling molecules encoded within mitochondrial DNA rather than nuclear DNA. It functions as a metabolic hormone, translocating to the nucleus under conditions of metabolic stress and activating AMPK-dependent gene expression.
Its relevance to testosterone restoration is through the metabolic-inflammatory-aromatase axis: MOTS-c improves insulin sensitivity, reduces glucose toxicity, promotes fatty acid oxidation, and reduces visceral adiposity. Each of these effects directly reduces the aromatase burden that converts testosterone to estradiol. Additionally, AMPK activation in Leydig cells has been shown to directly regulate steroidogenic enzyme expression — MOTS-c may have a direct testicular effect beyond its systemic metabolic action.
MOTS-c is introduced in Phase 3 rather than Phase 1 because its effects are most productive once the hormonal foundation is established. Adding a metabolic optimization layer before the cascade has been restored provides less benefit than adding it when rising T and IGF-1 levels create the anabolic environment in which AMPK-mediated improvements in body composition are most pronounced.
Start at 5 mg and assess response before increasing to 10 mg. Some subjects experience mild fatigue in the first few days as mitochondrial function shifts — this is transient and resolves within the first week.
PT-141 is included as an optional component that operates through an entirely independent mechanism from every other compound in this protocol. It is an MC3R and MC4R agonist — it acts on melanocortin receptors in the central nervous system, specifically in the hypothalamus and limbic system, to initiate sexual arousal and erectile function.
This distinction matters: PT-141 does not raise testosterone and does not interact with the HPG axis. It addresses the neural component of sexual function independently of hormonal status. This is clinically relevant because low libido and erectile dysfunction in aging men often have both hormonal and neural components — and the neural component can persist even as hormonal levels normalize. PT-141 addresses the neural component directly without waiting for the hormonal intervention to take full effect.
FDA-approved as Vyleesi for hypoactive sexual desire disorder, PT-141 has a well-characterized safety profile at standard research doses. Onset is 45–60 minutes post-injection; duration 6–12 hours. Mild nausea and flushing are the most common side effects, typically dose-dependent and manageable by starting at 0.5 mg.
Objective measurement is what separates a protocol from a guess. Pull a baseline panel before starting — this gives you the numbers to measure against, and it reveals any pre-existing conditions that might modify the approach (elevated PSA, suppressed LH suggesting prior TRT use, low-normal thyroid, etc.).
📊 Baseline Panel (Before Week 1)
📊 Week 6 Check-In
📊 Week 12 Full Panel
🚨 Flag These
Individual response varies based on baseline hormonal status, degree of suppressor burden, HCG sensitivity, and age. The timeline below reflects typical response patterns — earlier responders exist, as do late responders who see little in the first 4 weeks and then shift significantly in weeks 5–8.
Foundation Building — Mostly Silent
HCG and KLOW are doing their work, but subjective changes are minimal. Some subjects notice mild fluid retention from the GH 2X blend (if already introduced) as IGF-1 rises. Sleep may begin to improve. Occasional mild injection site reactions are possible but not expected. This phase requires patience — the changes happening at the cellular and signaling level are not yet visible.
First Signals — Testosterone Rising
Morning erections are often the first noticeable subjective marker of rising testosterone — typically appearing in Weeks 3–4 as HCG begins to produce meaningful ITT elevation. Energy levels begin to stabilize. Mood often improves subtly. Kisspeptin-10 is introduced at Week 3 — some subjects notice a further libido shift within the first 1–2 weeks of addition. The inflammatory environment is clearing as KLOW approaches its Phase 1 completion.
Build Phase — Compounding Effects
This is typically the most noticeably productive phase. The cascade is now running — HCG stimulating directly, Kisspeptin rebuilding the upstream signal, IGF-1 providing parallel Leydig support. Body composition changes begin — reduction in visceral fat, improved muscle fullness, subtle strength improvements in the gym. Cognitive clarity and motivation often improve. Libido is typically markedly better than baseline by Week 6–7. The Epitalon course runs at Week 6 — improved deep sleep quality is often noticed within a few days.
Peak Effect — Full Protocol Synergy
All compounds are now running simultaneously. This is where the compounding effect of multi-axis intervention becomes measurable. Week 12 bloodwork typically shows the most significant movement across all markers. Body composition changes are visible. Subjects who track subjective wellbeing metrics (mood, energy, libido, sleep quality) consistently report this as the best phase of the protocol.
Sustaining the Gains
Because this protocol works to restore signaling capacity rather than replace it, off-protocol testosterone levels are typically higher than pre-protocol baseline — the system has been better positioned to function on its own. The Epitalon effect on melatonin/sleep persists 3–6 months. IGF-1 may begin to decline slowly. LH pulsatility, once restored, tends to persist if the underlying suppressors have been meaningfully reduced. A second protocol run at 6–12 months is appropriate for sustained optimization.